Dual-mechanism fluorescence system and application thereof in preparation of auxiliary diagnosis kit for gastric cancer
The dual-mechanism fluorescence system addresses the limitations of current gastric cancer diagnostics by using ON-probes and OFF-probes to detect up-regulated and down-regulated miRNAs, enhancing fluorescence sensitivity and accuracy for early detection.
Patent Information
- Application Number
- CN202410998213.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-12-03
AI Technical Summary
Current gastric cancer diagnosis methods, such as gastroscopy and invasive tissue imaging, are costly, painful, and risky, while miRNA-based diagnostics lack accuracy and sensitivity for early detection.
A dual-mechanism fluorescence system using ON-probes and OFF-probes, where ON-probes are single-stranded DNA modified with a fluorescent group adsorbed on inorganic nanomaterials to enhance fluorescence upon binding to up-regulated markers, and OFF-probes are double-stranded DNA to quench fluorescence upon binding to down-regulated markers, specifically targeting miRNAs associated with gastric cancer.
The system provides a sensitive and non-invasive method for gastric cancer detection by analyzing fluorescence intensity changes, offering high accuracy and reproducibility, and can be used in early diagnosis kits.
Smart Images

Figure CN119060723A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of analytical chemistry, in particular to a dual-mechanism fluorescence system and application thereof in preparing a gastric cancer auxiliary diagnosis kit. Background Art
[0002] Gastric cancer ranks second among all tumors in my country. According to Global Cancer Statistics 2020, the 5-year survival rate of gastric cancer in my country is only 35.1%, which is much lower than 64.6% in Japan and 71.5% in South Korea. This is mainly attributed to the lack of early screening and diagnosis of gastric cancer in my country. At present, the clinical diagnosis of gastric cancer still relies on invasive methods combining tumor tissue imaging and pathological examination, which is often insensitive to early gastric cancer and may increase the risk of lesions. With the improvement of national health awareness, gastroscopy as a means of early gastric cancer screening has gradually been accepted by everyone. However, gastroscopy screening is not only costly, but also brings physical pain and certain risks to patients. In contrast, liquid biopsy based on biomarkers provides a sensitive and non-invasive method for diagnosing gastric cancer. At the same time, the complex pathological mechanism of gastric cancer makes the joint evaluation of multiple biomarkers very important.
[0003] miRNA is a type of endogenous small RNA with a length of about 20-24 nucleotides. It has a variety of important regulatory functions in cells. The development of cancer is accompanied by the upregulation or downregulation of the expression levels of various miRNAs. Therefore, miRNA has been used as a very mature biomarker for cancer diagnosis. However, most reports on gastric cancer diagnosis through miRNA are based on the content level of a certain microRNA, and the accuracy and sensitivity are difficult to meet the clinical diagnosis standards. Summary of the invention
[0004] In order to solve the above technical problems, the present invention provides a dual-mechanism fluorescence system, including an ON-probe and an OFF-probe modified by a fluorescent group, wherein the ON-probe is a single-stranded DNA, which specifically recognizes an up-regulated marker, and the OFF-probe is a double-stranded DNA, which specifically recognizes a down-regulated marker. The ON-probe is adsorbed on the surface of an inorganic nanomaterial, and after binding to an up-regulated marker, it detaches from the surface of the inorganic nanomaterial, and the fluorescence is enhanced. The single strand modified with a fluorescent group in the OFF-probe is replaced by the down-regulated marker, and the fluorescence is quenched. Three up-regulated miRNAs and three down-regulated miRNAs highly related to gastric cancer were screened through the TCGA database, and three ON-probes and three OFF-probes were designed accordingly. Changes in the content of the six miRNAs will cause changes in the fluorescence intensity in the reaction system. Cluster analysis of the fluorescence change results is performed through the K-means algorithm, which can assist in determining whether the sample to be tested suffers from gastric cancer.
[0005] The first object of the present invention is to provide a dual-mechanism fluorescence system, comprising an ON-probe and an OFF-probe, wherein the ON-probe specifically recognizes an up-regulated marker, and the OFF-probe specifically recognizes a down-regulated marker;
[0006] The ON-probe is a single-stranded DNA modified with a fluorescent group, which is adsorbed on the surface of the inorganic nanomaterial, and after binding to the up-regulated marker, it detaches from the surface of the inorganic nanomaterial, and the fluorescence is enhanced;
[0007] The OFF-probe is a double-stranded DNA, one of which is modified with a fluorescent group. The single strand modified with the fluorescent group is replaced by the down-regulation marker and adsorbed on the surface of the inorganic nanomaterial, where the fluorescence is quenched. The single strand not modified with the fluorescent group hybridizes with the down-regulation marker to form a double strand.
[0008] The second object of the present invention is to provide the use of the above dual-mechanism fluorescence system in the preparation of a gastric cancer auxiliary diagnosis kit.
[0009] The third object of the present invention is to provide a kit comprising a probe combination for identifying gastric cancer miRNA biomarkers and an inorganic nanomaterial for adsorbing single-stranded DNA;
[0010] The gastric cancer miRNA biomarkers include up-regulated markers and down-regulated markers, the up-regulated markers include miRNA-21, miRNA-18a and miRNA-20a, and the down-regulated markers include miRNA-133a, miRNA-133b and miRNA-30a;
[0011] The probe combination includes an ON-probe and an OFF-probe, wherein the ON-probe is a single-stranded DNA modified with a fluorescent group for identifying the up-regulated marker; and the OFF-probe is a double-stranded DNA, wherein one single-strand is modified with a fluorescent group for identifying the down-regulated marker.
[0012] Furthermore, the nucleotide sequence of miRNA-21 is shown as SEQ ID NO.1, the nucleotide sequence of miRNA-18a is shown as SEQ ID NO.2, the nucleotide sequence of miRNA-20a is shown as SEQ ID NO.3, the nucleotide sequence of miRNA-133a is shown as SEQ ID NO.4, the nucleotide sequence of miRNA-133b is shown as SEQ ID NO.5, and the nucleotide sequence of miRNA-30a is shown as SEQ ID NO.6.
[0013] Furthermore, the inorganic nanomaterial includes graphene oxide.
[0014] Further, the ON-probe includes ON-probe-21, ON-probe-18a and ON-probe-20a, and the OFF-probe includes OFF-probe-133a, OFF-probe-133b and OFF-probe-30a, wherein:
[0015] ON-probe-21 is used to identify miRNA-21, and the nucleotide sequence is shown in SEQ ID NO.7;
[0016] ON-probe-18a is used to identify miRNA-18a, and the nucleotide sequence is shown in SEQ ID NO.8;
[0017] ON-probe-20a is used to identify miRNA-20a, and the nucleotide sequence is shown in SEQ ID NO.9;
[0018] OFF-probe-133a is used to identify miRNA-133a, and the nucleotide sequence is shown in SEQ ID NO.10-11;
[0019] OFF-probe-133b is used to identify miRNA-133b, and the nucleotide sequence is shown in SEQ ID NO.12-13;
[0020] OFF-probe-30a is used to identify miRNA-30a, and the nucleotide sequence is shown in SEQ ID NO.14-15.
[0021] Furthermore, the kit also includes serum standards from healthy people and gastric cancer patients.
[0022] Furthermore, the fluorescent group is FAM, which is modified at the 5' end of the probe.
[0023] Furthermore, the method of use comprises the following steps:
[0024] Step S1, extracting total miRNA from the sample to be tested, adding the probe combination and the inorganic nanomaterial for co-incubation, and detecting the fluorescence change of the reaction system;
[0025] Step S2: cluster analysis is performed on the fluorescence change results using the K-means algorithm to assist in determining whether the sample to be tested is diseased.
[0026] Furthermore, the final concentration of the ON-probe in the reaction system is 10-50 mM.
[0027] Preferably, the final concentration of the ON-probe in the reaction system is 15 mM.
[0028] Furthermore, the final concentration of the OFF-probe in the reaction system is 20-50 mM.
[0029] Preferably, the final concentration of the OFF-probe in the reaction system is 40 mM.
[0030] Furthermore, serum standards (1 gastric cancer patient and 1 healthy person) were selected as the initial cluster centers, and then the distance between each sample and each cluster center was calculated, and each sample was assigned to the cluster center closest to it. Then, the cluster center was recalculated based on the currently assigned sample, and the above steps were repeated until the cluster center no longer changed, and the clustering result was obtained, which distinguished gastric cancer patients from healthy people.
[0031] The fourth object of the present invention is to provide the use of the above-mentioned kit in auxiliary diagnosis of gastric cancer.
[0032] Beneficial effects of the present invention:
[0033] The invention has a simple mechanism and strong versatility. Corresponding ON-probes or OFF-probes can be designed for different miRNAs to perform corresponding detection. The system is applied to the preparation of a gastric cancer auxiliary diagnosis kit, which can quickly convert gastric cancer-related miRNA signals in the serum of the subject to be tested into fluorescent signals, thereby judging whether the subject to be tested has a risk of gastric cancer by the change in fluorescence intensity. In addition, since the mechanism of inorganic nanomaterials adsorbing single-stranded DNA and causing changes in fluorescence intensity is very mature, it has stability and high reproducibility, and can be applied to the early auxiliary diagnosis of other diseases, with broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein
[0035] Figure 1 It is a schematic diagram of the process of the present invention;
[0036] Figure 2 The receiver operating curve (ROC curve) of the six up-regulated miRNAs and the six down-regulated miRNAs obtained through the TCGA database in Example 2 of the present invention;
[0037] Figure 3 is a scanning electron microscope image of graphene oxide in Example 3 of the present invention;
[0038] Figure 4 is an atomic force microscope image and a height map of graphene oxide in Example 3 of the present invention;
[0039] Figure 5These are the fluorescence kinetic images of the fluorescence "ON" and "OFF" dual mechanisms verified by taking miRNA-21 (A) and miRNA-133b (B) as examples in Example 3 of the present invention;
[0040] Figure 6 This is a result diagram of the non-denaturing polyacrylamide gel electrophoresis in Example 4 of the present invention to verify the formation of the fluorescent "ON" and "OFF" dual mechanism system, wherein lane 1 is a 20bp DNA Marker, lane 2 is ON-probe-21, lane 3 is a mixture of graphene oxide and ON-probe-21, lane 4 is a mixture of graphene oxide, ON-probe-21 and miRNA-21, lane 5 is a single-stranded OFF-probe-133b (shown in SEQ ID NO.10), lane 6 is a double-stranded OFF-probe-133b, lane 7 is a mixture of graphene oxide and OFF-probe-133b double-stranded, and lane 8 is a mixture of graphene oxide, OFF-probe-133b double-stranded and miRNA-133b.
[0041] Figure 7 It is a fluorescence kinetic diagram and a fluorescence enhancement efficiency bar diagram of optimizing the concentrations of ON-probes (A, B) and OFF-probes (C, D) in Example 5 of the present invention when the concentration of graphene oxide is constant;
[0042] Figure 8 It is a non-denaturing polyacrylamide gel electrophoresis diagram (A) and a fluorescence enhancement efficiency heat map (B) for verifying the orthogonal relationship between six probes and six miRNAs in Example 6 of the present invention;
[0043] Fig. 9 It is the fluorescence enhancement efficiency heat map (A) and standard curve (B, C) of detecting different concentrations of three up-regulated and three down-regulated miRNAs in Example 7 of the present invention;
[0044] Fig.10 It is a fluorescence kinetic diagram (A) and a fluorescence enhancement efficiency line graph (B) of the summed detection of two up-regulated miRNAs at different concentrations by the fluorescence "ON" mechanism in Example 8 of the present invention;
[0045] Fig.11 It is a fluorescence kinetic diagram (A) and a fluorescence enhancement efficiency line graph (B) of the additive detection of two down-regulated miRNAs at different concentrations by the fluorescence "OFF" mechanism in Example 8 of the present invention;
[0046] Fig.12 It is a fluorescence kinetic diagram (A) and a fluorescence enhancement efficiency line graph (B) of the additive detection of one up-regulated miRNA and one down-regulated miRNA at different concentrations by the fluorescence "ON" and "OFF" dual mechanisms in Example 8 of the present invention;
[0047] Fig.13 is a schematic diagram of implementing additive diagnosis with clinical serum samples in Example 9 of the present invention;
[0048] Fig.14 is a scatter plot of the fluorescence enhancement efficiency detected by summing different types of miRNA in clinical serum samples in Example 9 of the present invention;
[0049] Fig.15 This is the clustering result of training the fluorescence enhancement efficiency of the sum detection of six miRNAs in clinical serum samples in Example 9 of the present invention, where cluster A is healthy people and cluster B is gastric cancer patients. DETAILED DESCRIPTION
[0050] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0051] Reagents and materials:
[0052] DNA sequences were synthesized and purified by Sangon Biotechnology Co., Ltd. (Shanghai, China).
[0053] 40% acrylamide / bisacrylamide (29:1) solution, ammonium persulfate (APS), N,N,N′,N′-tetramethylethylenediamine (TEMED), Tris, and tetrasodium ethylenediaminetetraacetate (EDTA) were purchased from Sangon Biotechnology Co., Ltd. (Shanghai, China).
[0054] Gel Red nucleic acid gel stain was purchased from Thermo Fisher Scientific.
[0055] 20 bp DNA ladder and 6*Loading buffer were purchased from Bio-Ray Biomedical Technology Co., Ltd. (Beijing).
[0056] Graphene oxide was purchased from Jiangsu Xianfeng Nanomaterial Technology Co., Ltd.
[0057] Clinical serum was provided by Taizhou Branch of Zhejiang Cancer Hospital.
[0058] All other reagents were of analytical grade and used as received. Ultrapure water (18.25 mΩ·cm) obtained from a UP water purification system was used throughout the experiments.
[0059] Instruments and equipment:
[0060] The fluorescence intensity and fluorescence kinetics were recorded by Synergy H1 multifunctional microplate reader (Agilent BioTek, USA). Polyacrylamide gel electrophoresis was performed in a Bio-Rad vertical electrophoresis tank. The stained polyacrylamide gel was imaged on a GelDocTMXR+ imaging system (Bio-RAD Laboratories Inc., USA). Scanning electron microscopy (SEM) measurements were performed on a JEOL JSM-IT800 thermal field emission scanning electron microscope (JEOL, Japan). Atomic force microscopy (AFM) measurements were performed on a Bruker atomic force microscope MultiMode8 (Bruker, Germany). Others, unless otherwise specified, can be obtained from commercial sources.
[0061] Example 1: Screening of miRNA
[0062] The present invention extracted clinical data of multiple miRNAs from the public cancer database (TCGA), and screened out three up-regulated miRNAs and three down-regulated miRNAs with the strongest correlation with gastric cancer by the area under the curve (AUC) of the ROC curve. The ROC curve and AUC were shown in Figure 2. Figure 2 and Table 1. Up-regulated miRNA refers to the miRNA that is up-regulated in the serum samples of gastric cancer patients, and down-regulated miRNA refers to the miRNA that is down-regulated in the serum samples of gastric cancer patients.
[0063] Table 1 Area under the ROC curve (AUC) of six up-regulated miRNAs and six down-regulated miRNAs
[0064] Upregulation of miRNA sequence AUC Downregulation of miRNA sequence AUC miRNA-21 SEQ ID NO.1 0.9383 miRNA-133a SEQ ID NO.4 0.8642 miRNA-18a SEQ ID NO.2 0.82955 miRNA-133b SEQ ID NO.5 0.87422 miRNA-20a SEQ ID NO.3 0.80737 miRNA-30a SEQ ID NO.6 0.75973 miRNA-185 / 0.77417 miRNA-2b / 0.74541 miRNA-25 / 0.72326 miRNA-9-1 / 0.72002 miRNA-652 / 0.71367 miRNA-9-2 / 0.72077
[0065] Example 2: Design and preparation of probe
[0066] The present invention designs three ON-probes and three OFF-probes according to the sequences of three up-regulated miRNAs and three down-regulated miRNAs, respectively, wherein the ON-probe is a single-stranded DNA with a FAM fluorescent group, and the OFF probe is a partially complementary double-stranded DNA with a FAM fluorescent group.
[0067]
[0068]
[0069] Prepare the concentrated nucleic acid stock solution of the above sequence with TEPC water, dilute to the working solution concentration with HEPES buffer, heat the two chains of the OFF-probe at 95°C for 5 minutes, and slowly cool to room temperature. Store the annealed OFF-probe at 4°C for later use.
[0070] Example 3: Adsorption of graphene oxide on probe
[0071] (1) Structural verification of graphene oxide
[0072] 10 μL of graphene oxide solution was added to a clean silicon wafer, dried at room temperature, and then glued to the sample stage. The test was performed using a scanning electron microscope. The test results are shown in Figure 2. Figure 3 As shown, it is proved that graphene oxide is a lamellar structure. 10 μL of graphene oxide solution was added to the freshly peeled mica sheet and dried at room temperature. After loading, the sample was tested with ScanAsyst Air (Bruker, Germany) probe in Tapping mode. The test results of atomic force microscopy are shown in Figure 4 As shown, graphene oxide presents a micrometer-scale sheet structure, and the sheet thickness is about 1nm, proving that it is a single-layer structure.
[0073] (2) Adsorption of graphene oxide to probe and hybridization of miRNA to probe
[0074] For up-regulated miRNA-21, a mixed solution with a final concentration of 10 μg / mL of graphene oxide and a final concentration of 25 nM of ON-probe-21 was prepared with HEPES buffer. After incubation at room temperature for 2 hours, a fluorescence kinetic test was performed using a multifunctional microplate reader. For down-regulated miRNA-133b, a mixed solution with a final concentration of 10 μg / mL of graphene oxide and a final concentration of 25 nM of OFF-probe-133b was prepared with HEPES buffer. After incubation at room temperature for 2 hours, a fluorescence kinetic test was performed using a multifunctional microplate reader. The corresponding miRNAs were added to the above incubation solutions respectively. For the incubation solution of graphene oxide and ON-probe, miRNA-21 was added at a final concentration of 25 nM, and the fluorescence kinetic test was continued using a multifunctional microplate reader. For the incubation solution of graphene oxide and OFF-probe, miRNA-133b was added at a final concentration of 25 nM, and the fluorescence kinetic test was continued using a multifunctional microplate reader.
[0075] Test results such as Figure 5 As shown, for up-regulated miRNA, before the addition of miRNA-21, the fluorescence intensity was weak, while the addition of miRNA-21 gradually increased the fluorescence, and then maintained a strong fluorescence, proving that the fluorescence intensity increased with the addition of miRNA ( Figure 5 A). For down-regulated miRNA, the fluorescence intensity was strong before the addition of miRNA-133b, but the addition of miRNA-133b gradually weakened the fluorescence, and then maintained a weak fluorescence, proving that the fluorescence intensity weakened with the addition of miRNA ( Figure 5 B) The above results prove that the present invention has successfully constructed a biosensor for detecting multiple dysregulated miRNAs in gastric cancer based on the fluorescence "ON" and "OFF" dual mechanisms.
[0076] Example 4: Verification of the formation of the fluorescence "ON" and "OFF" dual mechanism system
[0077] An 8% polyacrylamide gel was prepared by mixing 1.2 mL of 40% acrylamide / bisacrylamide solution (29:1), 4.8 mL of 1×TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM EDTA, pH 8.0), 60 μL of 0.1 g / mL APS, and 6 μL of TEMED.
[0078] Take 5 μL of sample and mix with 1 μL of 6× loading buffer, and inject 6 μL of the mixture into the gel well. The gel is run in 1× TBE buffer at 4°C and 100V for 2 hours, stained with Gel Red for 20 minutes, and imaged with an imaging system.
[0079] The results are as follows Figure 6 As shown, lane 1 is a 20 bp DNA Marker, lane 2 is ON-probe-21, lane 3 is a mixture of graphene oxide and ON-probe-21, lane 4 is a mixture of graphene oxide, ON-probe-21 and miRNA-21, lane 5 is a single-stranded OFF-probe-133b (shown in SEQ ID NO.10), lane 6 is a double-stranded OFF-probe-133b, lane 7 is a mixture of graphene oxide and OFF-probe-133b double-stranded, and lane 8 is a mixture of graphene oxide, OFF-probe-133b double-stranded and miRNA-133b.
[0080] Lane 2 shows a lower band, Lane 3 shows no band, and Lane 4 shows an upper band, which proves that ON-probe-21 in Lane 3 is adsorbed on the surface of graphene oxide. It cannot migrate due to its large molecular weight, but after adding miRNA-21, a band is shown, which proves that miRNA-21 and ON-probe-21 hybridize to form a double-stranded structure and fall off from the surface of graphene oxide. Lane 5 shows a lower band, while Lane 6 shows an upper band, which proves that the two DNA chains in Lane 6 form a double-stranded OFF-probe-133b. The band positions of Lane 7 and Lane 6 are consistent, which proves that the double-stranded OFF-probe-133b will not be adsorbed on graphene oxide, while Lane 8 after adding miRNA-133b still shows a higher band, which proves that miRNA-21 and OFF-probe-133b hybridize to form a new double-stranded structure.
[0081] Example 5: Optimizing the concentration of ON-probe and OFF-probe
[0082] For the up-regulated miRNA-21, a mixed solution of graphene oxide with a final concentration of 10 μg / mL and ON-probe-21 with a final concentration of 0-50 nM was prepared with HEPES buffer. After incubation at room temperature for 2 hours, fluorescence kinetic tests were performed using a multifunctional microplate reader. After adding the corresponding concentration of miRNA-21, the fluorescence kinetic test was continued. For the down-regulated miRNA-133b, a mixed solution of graphene oxide with a final concentration of 10 μg / mL and OFF-probe-133b with a final concentration of 0-50 nM was prepared with HEPES buffer. After incubation at room temperature for 2 hours, fluorescence kinetic tests were performed using a multifunctional microplate reader. After adding the corresponding concentration of miRNA-133b, the fluorescence kinetic test was continued. The test results are as follows. Figure 7 A and Figure 7 As shown in C.
[0083] The fluorescence intensity at 0 hours (F0) and 4 hours (F) of the fluorescence kinetic test was selected to calculate the fluorescence enhancement efficiency [(F-F0) / F0]. The calculation results are as follows: Figure 7 B and Figure 7 As shown in D, it can be seen that the optimal concentration of the ON-probe is 15 nM, and the optimal concentration of the OFF-probe is 40 nM.
[0084] Example 6: Verification of the orthogonal relationship between probes and miRNA
[0085] (1) Non-denaturing polyacrylamide gel electrophoresis to verify the orthogonal relationship between the six probes and the six miRNAs
[0086] Non-denaturing polyacrylamide gel electrophoresis was used to test the orthogonal relationship between the three ON-probes and the three OFF-probes and the corresponding miRNAs. The gel preparation and imaging process were the same as in Example 4. The samples added to the lanes and the electrophoresis images are shown in FIG. Figure 8 As shown in A. All six probes hybridize only with the corresponding miRNAs, but not with other miRNAs, showing good specific recognition properties.
[0087] (2) Fluorescence enhancement efficiency heat map verifies the orthogonal relationship between the six probes and the six miRNAs
[0088] The orthogonal relationship between the three ON-probes and the three OFF-probes and the corresponding miRNAs was tested. The fluorescence enhancement efficiency heat map is shown in Figure 8 As shown in B. Only when the corresponding miRNA exists, the fluorescence enhancement efficiency will show a significant increase or decrease, which further proves the good specific recognition properties of the six probes.
[0089] Example 7: Detection of miRNA fluorescence enhancement efficiency at different concentrations
[0090] The concentrations of fixed graphene oxide, ON-probe and OFF-probe were 10 μg / mL, 15 nM and 40 nM, respectively. The fluorescence enhancement efficiency of three up-regulated and three down-regulated miRNAs at different concentrations was detected. The heat map and standard curve are shown in Fig. 9 As shown in the figure, for the ON-probe, the fluorescence enhancement efficiency increases with the increase of miRNA concentration, and both show a good linear relationship. For the OFF-probe, the fluorescence enhancement efficiency decreases with the increase of miRNA concentration, and both show a good linear relationship. The above results demonstrate the ability of the probe to detect up-regulated and down-regulated miRNA.
[0091] Example 8: Additive Detection of miRNA
[0092] 1. Additive detection of two upregulated miRNAs
[0093] The ON-probes of miRNA-21 and miRNA-18a were added to the graphene oxide solution at the same time and then incubated. Then, different concentrations of the two miRNAs were added to test the fluorescence kinetics. The fluorescence kinetics tested and the fluorescence enhancement efficiency calculated are shown in Fig.10 As shown, the fluorescence enhancement efficiency increases with the increase in the sum of the concentrations of the two up-regulated miRNAs, demonstrating that this mechanism can perform additive detection of the two up-regulated miRNAs.
[0094] 2. Additive detection of two down-regulated miRNAs
[0095] The OFF-probes of miRNA-133b and miRNA-133a were added to the graphene oxide solution at the same time and then incubated. Then, different concentrations of the two miRNAs were added to test the fluorescence kinetics. The fluorescence kinetics tested and the fluorescence enhancement efficiency calculated are shown in Fig.11 As shown, the fluorescence enhancement efficiency increases as the sum of the concentrations of the two up-regulated miRNAs decreases, demonstrating that additive detection of the two down-regulated miRNAs is possible.
[0096] 2. Additive detection of one up-regulated miRNA and one down-regulated miRNA
[0097] The ON-probe and OFF-probe of miRNA-21 and miRNA-133b were added to the graphene oxide solution at the same time and then incubated. Then, different concentrations of the two miRNAs were added to test the fluorescence kinetics. The fluorescence kinetics tested and the fluorescence enhancement efficiency calculated are shown in Fig.12 As shown, when the concentration of up-regulated miRNA in the reaction system increases and the concentration of down-regulated miRNA decreases, the fluorescence enhancement efficiency increases accordingly, proving that additive detection of one up-regulated miRNA and one down-regulated miRNA can be performed.
[0098] Example 9: Additive detection of miRNA in serum samples for early diagnosis of gastric cancer
[0099] like Fig.13 As shown, total miRNA was first extracted from clinical serum samples, and then added to the 6 miRNA arbitrary adders (SUM-1 to SUM-6) designed by us to perform summation calculation on the miRNA.
[0100] like Fig.14 It can be seen that the fluorescence enhancement efficiency of gastric cancer patients in the six miRNA arbitrary adders was significantly higher than that of healthy individuals, but with the increase in the number of probe types, the differentiation boundary became more obvious, proving that the addition calculation of multiple miRNAs can improve the diagnostic accuracy.
[0101] like Fig.15 It can be seen that the K-Means algorithm is used to train the data obtained by summing up the 6 miRNAs in clinical serum samples (17 gastric cancer patients and 8 healthy people). First, 2 clinical serum samples (1 gastric cancer patient and 1 healthy person) are selected as the initial cluster centers, and then the distance between each sample and each cluster center is calculated, and each sample is assigned to the cluster center closest to it. Then, the cluster center is recalculated according to the currently assigned sample, and the above steps are repeated until the cluster center no longer changes, and the cluster results are obtained, where cluster A is a healthy person sample and cluster B is a gastric cancer patient sample. Through the clustering process, gastric cancer patients and healthy people can be distinguished, and accurate diagnosis of gastric cancer patients can be achieved.
[0102] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.
Claims
1. A dual-mechanism fluorescence system, characterized in that: It comprises an ON-probe and an OFF-probe, wherein the ON-probe specifically recognizes an up-regulated marker, and the OFF-probe specifically recognizes a down-regulated marker; The ON-probe is a single-stranded DNA modified with a fluorescent group, which is adsorbed on the surface of the inorganic nanomaterial, and after binding to the up-regulated marker, it detaches from the surface of the inorganic nanomaterial, and the fluorescence is enhanced; The OFF-probe is a double-stranded DNA, one of which is modified with a fluorescent group. The single strand modified with the fluorescent group is replaced by the down-regulation marker and adsorbed on the surface of the inorganic nanomaterial, where the fluorescence is quenched. The single strand not modified with the fluorescent group hybridizes with the down-regulation marker to form a double strand.
2. Use of the dual-mechanism fluorescence system according to claim 1 in preparing a gastric cancer auxiliary diagnosis kit.
3. A kit, characterized in that: Includes probe combinations for identifying gastric cancer miRNA biomarkers and inorganic nanomaterials for adsorbing single-stranded DNA; The gastric cancer miRNA biomarkers include up-regulated markers and down-regulated markers, the up-regulated markers include miRNA-21, miRNA-18a and miRNA-20a, and the down-regulated markers include miRNA-133a, miRNA-133b and miRNA-30a; The probe combination includes an ON-probe and an OFF-probe, wherein the ON-probe is a single-stranded DNA modified with a fluorescent group for identifying the up-regulated marker; and the OFF-probe is a double-stranded DNA, wherein one single-strand is modified with a fluorescent group for identifying the down-regulated marker.
4. The kit according to claim 3, characterized in that: The inorganic nanomaterial includes graphene oxide.
5. The kit according to claim 3, characterized in that The ON-probes include ON-probe-21, ON-probe-18a and ON-probe-20a, and the OFF-probes include OFF-probe-133a, OFF-probe-133b and OFF-probe-30a, wherein: ON-probe-21 is used to identify miRNA-21, and the nucleotide sequence is shown in SEQ ID NO.7; ON-probe-18a is used to identify miRNA-18a, and the nucleotide sequence is shown in SEQ ID NO.8; ON-probe-20a is used to identify miRNA-20a, and the nucleotide sequence is shown in SEQ ID NO.9; OFF-probe-133a is used to identify miRNA-133a, and the nucleotide sequence is shown in SEQ ID NO.10-11; OFF-probe-133b is used to identify miRNA-133b, and the nucleotide sequence is shown in SEQ ID NO.12-13; OFF-probe-30a is used to identify miRNA-30a, and the nucleotide sequence is shown in SEQ ID NO.14-15.
6. The kit according to claim 3, characterized in that: The kit also includes serum standards from healthy subjects and gastric cancer patients.
7. The kit according to claim 3, characterized in that: The fluorescent group is FAM, which is modified at the 5' end of the probe.
8. The kit according to claim 3, characterized in that The method of use includes the following steps: Step S1, extracting total miRNA from the sample to be tested, adding the probe combination and the inorganic nanomaterial for co-incubation, and detecting the fluorescence change of the reaction system; Step S2: cluster analysis is performed on the fluorescence change results using the K-means algorithm to assist in determining whether the sample to be tested is diseased.
9. The kit according to claim 8, characterized in that: The final concentration of the OFF-probe in the reaction system is 20-50 mM.
10. Use of the kit according to any one of claims 3 to 9 in auxiliary diagnosis of gastric cancer.
